Sleep and Pain Medications

Sleep medications and analgesics are almost universally symptomatic — they improve sleep or reduce pain without identifying why these were disturbed. The exceptions are DORAs (diagnostic for orexin tone) and cholestyramine (diagnostic for bile acid malabsorption).

1 Sleep Medications

Sleep medications are almost universally symptomatic — they improve sleep quality without identifying why sleep was poor. Melatonin carries possible circadian anti-inflammatory synergy with LDN + NAD+. Gabapentin increases N3 duration but may produce physiologically abnormal deep sleep and worsens OSA (AHI increase). Z-drugs may impair glymphatic clearance (NE oscillation suppression ~50% in animal models).

The one class-level differential worth isolating is the DORAs (dual orexin receptor antagonists — suvorexant, lemborexant, daridorexant). If a DORA improves sleep without worsening daytime fatigue, orexin signaling is dysregulated (circadian misalignment). If a DORA worsens daytime fatigue, orexin is globally deficient — in which case DORAs are contraindicated and orexin agonists become the relevant direction instead.

Certainty Low — theoretical framework, no ME/CFS clinical data.

Key caveat: Z-drugs may impair glymphatic clearance (~50% suppression of NE oscillation in animal models), and gabapentin worsens obstructive sleep apnea (AHI increase) — both risks matter more in ME/CFS, where sleep architecture and clearance are already compromised.

2 Pain Medications

Analgesics, neuropathic pain medications, and opioids are universally symptomatic with minimal diagnostic signal. NSAIDs carry aspirin/HIT contraindication.

Key caveat: Opioids carry a specific ME/CFS warning — by masking pain, they can enable overexertion beyond the energy envelope, paradoxically worsening PEM. Symptomatic pain relief here can drive the disease process in the wrong direction.

2.1 Compendium

The full pharmacodiagnostic entries for individual sleep and pain medications — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — are at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, individual entries: Zolpidem, Trazodone, Gabapentin/Pregabalin, Oxycodone, and related entries).